Rise in dining out sparks food waste concerns
The restaurant industry is rebounding, prompting discussions on its environmental impact through food waste.
Stockhead
SECOS leads global trend on sustainable packaging
As the world shifts to sustainable packaging, Australian leader SECOS looks positioned to capitalise.
Three ASX firms driving decarbonisation
Several ASX companies are focused on reducing CO2 emissions through their technologies and products. Here are just a few.
SECOS fights potential compostable bin liner ban in VIC
SECOS believes that the adoption of the proposal will increase landfill waste and lead to higher costs.
More Stories
ASX health stocks hit resistance
ASX health stocks have fallen for the first week of the 2025 financial year as capital raises remains major theme.
PharmAust turns heads with ALS treatment trial
PharmAust has hit a major trial-stage milestone for its monepantel investigational drug – designed to treat amyotrophic lateral sclerosis (ALS).
PharmAust raises $7.8mn in hot SPP
PharmAust has raised $7.8m in a strongly backed share purchase plan as moves to advance its lead drug monepantel to treat ALS.
The ASX is really in the red at lunch
Local markets have backtracked on Thursday after a Wall Street retreat.
Health stocks up in ‘fairly lacklustre week’
ASX health are up following what Morgans analyst Scott Power describes as a ‘fairly lacklustre week’.
Good news for antidepressant trial
Data shows that Actinogen’s lead drug, Xanamem, has consistently improved depression symptoms at a 10mg dose.
Positive interim results from PharmAust study
PharmAust has released positive interim results of its ongoing OLE study of monepantel to treat Amyotrophic Lateral Sclerosis.
PharmAust could sky-rocket if drug succeeds: Morgans
PharmAust’s monepantel is generating excitement with MND/ALS therapy, with Morgans predicting a potential stock price surge.
ASX choppy; BPM soars on Mt Gibson find
The ASX was choppy ahead of Fed decision, while BPM surged on its promising gold find near Mt Gibson.
ASX stocks driving clinical trials in Australia
The clinical trials sector has become a valuable sector and an asset to the Australian economy.
Original URL: https://www.ntnews.com.au/business/stockhead/page/200